Molecular docking studies, biological and toxicity evaluation of dihydroisoquinoline derivatives as potential anticancer agents.
We report a study of a series of isoquinoline derivatives, including their synthesis, in vitro microsomal leucine aminopeptidase (LAP) inhibition and antiproliferative activity on cancer cell lines. Among fourteen tested compounds, one (compound 3b) was determined to have good activity against LAP and significant antiproliferative activity against HL-60 human promyelocytic leukemia, Burkitt's lymphoma Raji, camptothecin resistant CEM/C2 leukemia cells with mutated catalytic site of topoisomerase I, its parental cell line CCRF/CEM and LoVo colon cancer. Its influence on the cell cycle was also observed. Moreover, we have confirmed that antiproliferative activity towards cancer cells is due to LAP inhibition. Docking simulation based on positioning compound 3b into the LAP active site was performed to explore the possible binding mode. The compound was able to form hydrogen bonds with Gly362 and coordinate zinc ions, which was previously suggested to be essential for inhibitory activity. Compound 3b was also characterized with a good selectivity index for cancer versus normal mammalian cells. Toxicological studies involving examination of skin sensitization, acute skin irritation/corrosion, acute dermal toxicity, acute oral toxicity and acute eye irritation/corrosion established that compound 3b is safe for use.
National Institute of Public Health-National Institute of Hygiene, Laboratory of Biologically Active Compounds, 24 Chocimska Str., 00-791 Warsaw, Poland.
Joanna
J
Ziemska
National Institute of Public Health-National Institute of Hygiene, Laboratory of Biologically Active Compounds, 24 Chocimska Str., 00-791 Warsaw, Poland.
Adam
A
Guśpiel
Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla Str.12, 53-114 Wroclaw, Poland.
Joanna
J
Jarosz
Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla Str.12, 53-114 Wroclaw, Poland.
Anna
A
Nasulewicz-Goldeman
Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla Str.12, 53-114 Wroclaw, Poland.
Joanna
J
Wietrzyk
Institute of Chemistry, Siedlce University, 3.Maja 54, Siedlce 80-110, Poland.
Robert
R
Kawęcki
Institute of Chemistry, Siedlce University, 3.Maja 54, Siedlce 80-110, Poland.
Krzysztof
K
Pypowski
National Medicines Institute, 30/34 Chelmska Str., 00-725 Warsaw, Poland.
Małgorzata
M
Jarończyk
National Institute of Public Health-National Institute of Hygiene, Laboratory of Biologically Active Compounds, 24 Chocimska Str., 00-791 Warsaw, Poland. Electronic address: jsolecka@pzh.gov.pl.
Jolanta
J
Solecka
D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D049109:Cell Proliferation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D018922:HL-60 Cells; D006801:Humans; D007546:Isoquinolines / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D062105:Molecular Docking Simulation; D015394:Molecular Structure; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; C109853:G 1617; D007546:Isoquinolines
Antiproliferative activity; Docking study; Leucine aminopeptidase; Toxicity